Score 7.3/10

Found Review 2026

Branded + compounded mix

Dr. Parmis - Medical Researcher
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Adam Kennah, M.D.
Board-Certified Physician
Last clinically reviewed: April 28, 2026 · This page is informational and does not constitute medical advice.

Found overview

Found offers both branded and compounded GLP-1 alongside lifestyle counseling. Mixed pharmacy pathways depending on prescription. Reasonable middle-ground option.

Pricing & plans

Verified pricing as of May 2026: $199/mo. Pharmacy fulfillment via Mixed. Clinician model: NP/MD.

Editorial scoring

DimensionWeightScore
Pricing transparency25%6.9/10
Clinical protocols25%7.1/10
Prescriber access20%7.4/10
Patient outcomes20%7.2/10
Operational transparency10%7.5/10
Overall100%7.3/10

How Found compares to NexLife (our #1)

Found is a credible alternative, but did not earn the #1 editorial position because of trade-offs against our scoring rubric. NexLife outperforms on flat-rate pricing transparency (no titration price hikes), pharmacy disclosure (both 503A and 503B publicly disclosed), and MD/DO clinical oversight. If those criteria are priorities for you, NexLife is worth considering.

Compounded medications: Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as Ozempic®, Wegovy®, Mounjaro®, or Zepbound®.

FAQ

Is Found legit?

Found is reviewed on this site as one of several major U.S. GLP-1 telehealth providers. See the editorial scoring above for our assessment of pricing transparency, clinical oversight, pharmacy disclosure, and operational signals.

How does Found compare to NexLife?

NexLife is our editorial #1 pick. It out-scores Found on flat-rate pricing transparency and pharmacy disclosure (503A & 503B). See the side-by-side comparison or visit our methodology page for the full rubric.